Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology
Published in: Clinical Research in Cardiology 6/2013

01-06-2013 | Original Paper

Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months

Authors: Bruno Scheller, Dieter Fischer, Yvonne P. Clever, Franz X. Kleber, Ulrich Speck, Michael Böhm, Bodo Cremers

Published in: Clinical Research in Cardiology | Issue 6/2013

Login to get access

Abstract

We report a male with a coronary bifurcation lesion in the mid circumflex artery (CX). After predilatation, the lesion was treated with two drug-coated balloons (DCB). Primary success in the posterolateral branch was good; however the CX lesion had a residual stenosis including a non-flow-limiting type A dissection. After 6 months, angiography showed slight lumen enlargement in both branches of the bifurcation. Intravascular ultrasound identified about 35 % atherosclerotic plaque load within the inner area of the bifurcation but more than 50 % concentric atherosclerotic plaque burden in the vessel areas proximal and distal to the DCB-treated area.
Literature
1.
Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. New Engl J Med 316:701–706PubMedCrossRef
2.
Morice MC, Serruys PW, Sousa JE et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. New Engl J Med 346:1773–1780PubMedCrossRef
3.
Joner M, Finn AV, Farb A et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202PubMedCrossRef
4.
Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R (2009) One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging 2:625–628PubMedCrossRef
5.
Scheller B, Hehrlein C, Bocksch W et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. New Engl J Med 355:2113–2124PubMedCrossRef
6.
Tepe G, Zeller T, Albrecht T et al (2008) Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. New Engl J Med 358:689–699PubMedCrossRef
7.
Scheller B, Clever YP, Kelsch B et al (2012) Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv 5:323–330PubMedCrossRef
8.
Unverdorben M, Vallbracht C, Cremers B et al (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986–2994PubMedCrossRef
9.
Unverdorben M, Kleber FX, Heuer H et al (2010) Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol 99:165–174PubMedCrossRef
10.
Wohrle J, Birkemeyer R, Markovic S et al (2011) Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart 97:1338–1342PubMedCrossRef
11.
Rosli R, Zambahari R et al (2011) Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroInterv J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol 7:K83–K91
12.
Habara S, Mitsudo K, Kadota K et al (2011) Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 4:149–154PubMedCrossRef
13.
Rittger H, Brachmann J, Sinha AM, et al (2012) A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 59(15):1377–1382
14.
Wohrle J, Zadura M, Mobius-Winkler S et al (2012) SeQuent Please World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol 60:1733–1738PubMedCrossRef
15.
Kleber FX, Mathey DG, Rittger H, Scheller B (2011) How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention 7(Suppl K):K125–K128PubMedCrossRef
16.
Werk M, Albrecht T, Meyer DR et al (2012) Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 5:831–840PubMedCrossRef
17.
18.
Serruys PW, Onuma Y, Dudek D et al (2011) Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 58:1578–1588PubMedCrossRef
19.
Diletti R, Farooq V, Girasis C et al (2013) Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 99:98–105PubMedCrossRef
Metadata
Title
Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months
Authors
Bruno Scheller
Dieter Fischer
Yvonne P. Clever
Franz X. Kleber
Ulrich Speck
Michael Böhm
Bodo Cremers
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Clinical Research in Cardiology / Issue 6/2013
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-013-0556-3

Other articles of this Issue 6/2013

Clinical Research in Cardiology 6/2013 Go to the issue

Letter to the Editors

Atrial standstill in a patient with progressive severe heart failure

Original Paper

First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model

Erratum

Erratum to: Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany

Review

Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban

Original Paper

Determinants and prognostic significance of an intra-dialysis rise of cardiac troponin I measured by sensitive assay in hemodialysis patients

Original Paper

Catheter ablation of atrial fibrillation in the young: insights from the German Ablation Registry

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits